

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)



(10) International Publication Number
WO 2021/262881 A1

(51) International Patent Classification:

A61K 31/4192 (2006.01) *A61K 45/06* (2006.01)
A61K 31/635 (2006.01) *A61P 35/00* (2006.01)
A61K 31/706 (2006.01) *A61P 35/02* (2006.01)
A61K 31/7068 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/038741

(22) International Filing Date:

23 June 2021 (23.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/043,350 24 June 2020 (24.06.2020) US

(71) Applicant: **SERVIER PHARMACEUTICALS, LLC**
[US/US]; 200 Pier Four Boulevard, 7th Floor, Boston, MA
02110 (US).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(72) Inventors: **COCO, John**; 114 Rosemont Drive, North Andover, MA 01845 (US). **MURTIE, Joshua**; 34 Franklin Road, Winchester, MA 01890 (US). **ULANET, Danielle**; 126 Montgomery Street, Unit 3, Cambridge, MA 02140 (US).


(74) Agent: **DAVIS, Steven, G.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY

(57) Abstract: Provided herein are method of treating cancers using a first anti-cancer agent and at least one second anti-cancer agent, wherein the first anti-cancer agent is represented by Formula (I); or a pharmaceutically acceptable salt thereof. Compositions comprising the disclosed first anti-cancer agent and at least one second anti-cancer agent are also provided.



WO 2021/262881 A1